Australia markets closed

QURE Jul 2023 40.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.80000.0000 (0.00%)
As of 02:10PM EST. Market open.
Full screen
Previous close1.8000
Open1.8000
Bid0.0000
Ask0.0000
Strike40.00
Expiry date2023-07-21
Day's range1.8000 - 1.8000
Contract rangeN/A
Volume10
Open interest2.46k
  • Motley Fool

    3 Growth Stocks That Could Rocket Higher in 2023

    If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.

  • GlobeNewswire

    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 (the “Grant Dates”) each in accordance with

  • GlobeNewswire

    uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

    If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogen